Kiniksa Pharmaceuticals International, plc
- KNSA
- NASDAQ
- Medical - Pharmaceuticals
- Anti-IL-1 Therapies
- Rare Disease (Recurrent Pericarditis)
$79.48
Today +1.13%Quote Oct 19, 2026, 08:00 PM UTC
−0.93%over the last month
Max drawdown −5.9%From 1-month high −1.7%3 months +25.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Employees
366
Founded
2015
Market value
$6.20B
Quote Oct 19
Floor
$79.45
0.0% below price
Resistance
$80.80
1.7% above price
Price vs analyst targets
11 analysts
Lowest target
$71.00Highest target
$99.00
$71.00Highest target
$99.00
- Price $79.48
- Average target $86.40
- Analysts' target range
Analysts' average target sits about 9% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KNSAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free